Mannowetz, N., Chung, S. S. W., Maitra, S., Noman, M. A. A., Wong, H. L., Cheryala, N., Bakshi, A., Wolgemuth, D. J., & Georg, G. I. (2025). Targeting the retinoid signaling pathway with YCT-529 for effective and reversible oral contraception in mice and primates. Communications Medicine, 5(1). https://doi.org/10.1038/s43856-025-00752-7

Huang, Y., Kwan, M. L., Heckbert, S. R., Smith, N. L., Othus, M., Laurent, C. A., Roh, J. M., Rillamas-Sun, E., Lee, V. S., Kolevska, T., Cheng, R. K., Irribarren, C., Nguyen-Huynh, M., Hershman, D. L., Kushi, L. H., & Greenlee, H. (2025). Duration of aromatase inhibitor use and long-term cardiovascular risk in breast cancer survivors. JNCI Cancer Spectrum. https://doi.org/10.1093/jncics/pkaf009

MacInnis, R. J., Jenkins, M. A., Milne, R. L., John, E. M., Daly, M. B., Andrulis, I. L., Colonna, S. V., Phillips, K.-A., Le Marchand, L., Newcomb, P. A., Phipps, A. I., Schmit, S. L., Macrae, F. A., Buchanan, D. D., Gallinger, S., Pai, R. K., Samadder, N. J., Giles, G. G., … Terry, M. B. (2024). Menopausal hormone therapy: assessing associations with breast and colorectal cancers by familial risk. JNCI Cancer Spectrum, 9(1). https://doi.org/10.1093/jncics/pkae121

Serrano, D., Johansson, H., Bertelsen, B.-E., Gandini, S., Mellgren, G., Thomas, P., Crew, K. D., Kumar, N. B., Macis, D., Aristarco, V., Guerrieri-Gonzaga, A., Lazzeroni, M., D’Amico, M., Buttiron-Webber, T., Briata, I. M., Spinaci, S., Galimberti, V., Vornik, L. A., Villar-Sanchez, E., … DeCensi, A. (2024). Drug and biomarker tissue levels in a randomized presurgical trial on exemestane alternative schedules. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djae183

Oveisgharan, S., Yu, L., de Paiva Lopes, K., Petyuk, V. A., Tasaki, S., Vialle, R., Menon, V., Wang, Y., De Jager, P. L., Schneider, J. A., & Bennett, D. A. (2024). G-protein coupled estrogen receptor 1, amyloid-β, and tau tangles in older adults. Communications Biology, 7(1). https://doi.org/10.1038/s42003-024-06272-9

Johansson, H., Guerrieri-Gonzaga, A., Gandini, S., Bertelsen, B.-E., Macis, D., Serrano, D., Mellgren, G., Lazzeroni, M., Thomas, P. S., Crew, K. D., Kumar, N. B., Briata, I. M., Galimberti, V., Viale, G., Vornik, L. A., Aristarco, V., Buttiron Webber, T., Spinaci, S., Brown, P. H., … DeCensi, A. (2024). Alternative dosing regimen of exemestane in a randomized presurgical trial: the role of obesity in biomarker modulation. Npj Breast Cancer, 10(1). https://doi.org/10.1038/s41523-024-00616-8

Chemerinski, A., Valero-Pacheco, P. N., Shen, M., Murphy, T., George, L., Zhao, Q., Morelli, S., Heller, D., Chen, X., Arora, R., Beaulieu, A., & Douglas, N. (2023). THE IMPACT OF OVARIAN STIMULATION ON ENDOMETRIAL HISTOLOGY AND THE ENDOMETRIAL IMMUNOVASCULAR COMPARTMENT. Fertility and Sterility, 120(1), e13. https://doi.org/10.1016/j.fertnstert.2023.05.027

Sweat, M., Foidart, J., Utian, W., Gerard, C., Chatel, G., Gaspard, U., Taziaux, M., & Lobo, R. (2023). (068) Low Drug-Drug interaction risk of Estetrol (E4), a Promising New Estrogen for the Treatment of Menopausal Symptoms. The Journal of Sexual Medicine, 20(Supplement_2). https://doi.org/10.1093/jsxmed/qdad061.064

Gaspard, U., Taziaux, M., Jost, M., Coelingh Bennink, H. J. T., Utian, W. H., Lobo, R. A., & Foidart, J.-M. (2023). A multicenter, randomized, placebo-controlled study to select the minimum effective dose of estetrol in postmenopausal participants (E4Relief): part 2—vaginal cytology, genitourinary syndrome of menopause, and health-related quality of life. Menopause, 30(5), 480–489. https://doi.org/10.1097/gme.0000000000002167

Oveisgharan, S., Yang, J., Yu, L., Burba, D., Bang, W., Tasaki, S., Grodstein, F., Wang, Y., Zhao, J., De Jager, P. L., Schneider, J. A., & Bennett, D. A. (2023). Estrogen Receptor Genes, Cognitive Decline, and Alzheimer Disease. Neurology, 100(14). https://doi.org/10.1212/wnl.0000000000206833

Douxfils, J., Gaspard, U., Taziaux, M., Jost, M., Bouvy, C., Lobo, R. A., Utian, W. H., & Foidart, J.-M. (2022). Impact of estetrol (E4) on hemostasis, metabolism and bone turnover in postmenopausal women. Climacteric, 26(1), 55–63. https://doi.org/10.1080/13697137.2022.2139599

Fontana, E., Williams, A., Falchook, G., Lakhani, N., Evans, T. R. J., Gondi, V., Iwamoto, F., McKean, M., Symeonides, S., Butowski, N., McLaren, A., Henry, J., Buerki, R., Rotolo, J., Capiaux, G., Michel, R., Kaesshaefer, S., Wiegert, E., & Bexon, A. (2022). Efficacy signals, long-term exposure and safety data from a phase 1–2 study of a cell-penetrating peptide antagonist of CEBPβ, a novel target, in patients (pts) with refractory solid tumors. European Journal of Cancer, 174, S82–S83. https://doi.org/10.1016/s0959-8049(22)01018-8